Mural Total Other Income Expense Net from 2010 to 2025

MURA Stock   3.85  0.02  0.52%   
Mural Oncology's Total Other Income Expense Net is decreasing over the years with slightly volatile fluctuation. Total Other Income Expense Net is expected to dwindle to about 5.2 M. From 2010 to 2025 Mural Oncology Total Other Income Expense Net quarterly data regression line had arithmetic mean of  9,196,908 and significance of  0.06. View All Fundamentals
 
Total Other Income Expense Net  
First Reported
2010-12-31
Previous Quarter
9.7 M
Current Value
5.2 M
Quarterly Volatility
2.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Mural Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mural Oncology's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 2 M or Selling General Administrative of 27.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.41. Mural financial statements analysis is a perfect complement when working with Mural Oncology Valuation or Volatility modules.
  
Check out the analysis of Mural Oncology Correlation against competitors.

Latest Mural Oncology's Total Other Income Expense Net Growth Pattern

Below is the plot of the Total Other Income Expense Net of Mural Oncology plc over the last few years. It is Mural Oncology's Total Other Income Expense Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mural Oncology's overall financial position and show how it may be relating to other accounts over time.
Total Other Income Expense Net10 Years Trend
Slightly volatile
   Total Other Income Expense Net   
       Timeline  

Mural Total Other Income Expense Net Regression Statistics

Arithmetic Mean9,196,908
Coefficient Of Variation31.67
Mean Deviation1,736,285
Median10,223,000
Standard Deviation2,913,072
Sample Variance8.5T
Range10.9M
R-Value(0.49)
Mean Square Error7T
R-Squared0.24
Significance0.06
Slope(296,800)
Total Sum of Squares127.3T

Mural Total Other Income Expense Net History

20255.2 M
20249.7 M
2023-649 K

About Mural Oncology Financial Statements

Mural Oncology stakeholders use historical fundamental indicators, such as Mural Oncology's Total Other Income Expense Net, to determine how well the company is positioned to perform in the future. Although Mural Oncology investors may analyze each financial statement separately, they are all interrelated. For example, changes in Mural Oncology's assets and liabilities are reflected in the revenues and expenses on Mural Oncology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Mural Oncology plc. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Other Income Expense Net9.7 M5.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Mural Oncology plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mural Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mural Oncology Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mural Oncology Plc Stock:
Check out the analysis of Mural Oncology Correlation against competitors.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mural Oncology. If investors know Mural will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mural Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(7.58)
Return On Assets
(0.37)
Return On Equity
(0.64)
The market value of Mural Oncology plc is measured differently than its book value, which is the value of Mural that is recorded on the company's balance sheet. Investors also form their own opinion of Mural Oncology's value that differs from its market value or its book value, called intrinsic value, which is Mural Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mural Oncology's market value can be influenced by many factors that don't directly affect Mural Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mural Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mural Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mural Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.